[June 23, 2014] |
|
BIO Elects New Board Members and Officers for the 2014-2015 Term
SAN DIEGO --(Business Wire)--
The Biotechnology
Industry Organization (BIO) is pleased to announce the re-election
of Rachel King, President & CEO, GlycoMimetics, Inc., as the Chair of
its Board of Directors for the 2014-2015 term, the election of Dan
Junius, President & CEO, ImmunoGen, as its new Board Treasurer, and the
re-election of David Pyott, Chairman, President & CEO, Allergan, Inc.,
as Board Secretary. The Board also elected 19 of its Directors to serve
on BIO's Board Executive Committee for the new term. In addition, BIO
welcomes the election of 10 new members to its Board of Directors, voted
upon at this year's 2014
BIO International Convention.
"We welcome our new officers and Board members, and are looking forward
to working with them to create a more favorable policy, legislative and
business development environment for the global biotech industry," said
Jim Greenwood, BIO President & CEO. "This newly-constituted Board of
Directors brings significant industry experience and passion that will
serve BIO and its members well."
Greenwood also thanked BIO's departing Board members, saying, "BIO is
deeply appreciative to departing Board members for their dedication and
commitment over the years."
Members of the Executive Committee of BIO's Board of Directors for the
2014-2015 term are:
-
Rachel King, President & CEO, GlycoMimetics - Board and Executive
Committee Chair
-
Dan Junius, President & CEO, ImmunoGen - Board Treasurer
-
David Pyott, Chairman, President & CEO, Allergan - Board Secretary
-
Ron Cohen, President & CEO, Acorda Therapeutics - Health Section
Governing Board Vice Chair
-
John Maraganore, Chief Executive Officer, Emerging Companies Section
(ECS) Governing Board Chair
-
Michael Narachi, President & CEO, Orexigen Therapeutics - ECS
Governing Board Vice Chair
-
Jerry Flint, Vice President, Biotech Affairs and Regulatory, DuPont -
Food & Agriculture Section (FAS) Governing Board Chair
-
Eddie Sullivan, President & CEO, SAB Biotherapeutics - FAS Governing
Board Vice Chair
-
Adam Monroe, President, Novozymes North America- Industrial &
Environmental Section (IES) Governing Board Chair
-
Christopher Standlee, Executie Vice Present, Institutional
Relationships & Government Affairs, Abengoa Bioenergy - IES Governing
Board Vice Chair
-
Ian Clark, CEO & Head of North American Commercial Operations,
Genentech/Roche - At-Large
-
Doug Doerfler, President & CEO, MaxCyte - At-Large
-
Julie Gerberding, President, Merck Vaccines - At-Large
-
Geno Germano, President and General Manager of Specialty Care and
Oncology, Pfizer - At-Large
-
Paul Hastings (News - Alert), President & CEO, OncoMed Pharmaceuticals - At-Large
-
Perry Karsen, Chief Operations Officer, Celgene - At-Large
-
Richard Pops, Chairman & CEO, Alkermes - At-Large
-
Jay Siegel, Chief Biotechnology Officer & Head Scientific Strategy &
Policy, Johnson & Johnson - At-Large
-
H. Thomas Watkins - Immediate Past Chair/Chair Emeritus
The full BIO Board of Directors is comprised of the elected Directors
serving on each of BIO's Section Governing Boards. The newly-elected
Board Members from these Sections are:
Health Section Governing Board
-
John Glasspool, Vice President, Emerging Therapies and Market
Development, Baxter Bioscience
-
Flemming Ornskov, Chief Executive Officer, Shire, plc
-
Paris Panayiotopoulos, President & Managing Director, EMD Serono, Inc.
-
Michael Severino, Executive Vice President and R&D Chief Scientific
Officer, AbbVie
-
Mark Timney, President & CEO, Purdue Pharma
Emerging Companies Section Governing Board
-
Deborah Dunsire, President & CEO, FORUM Pharmaceuticals
-
Jean-Francois Formela, Partner, Atlas Venture
-
Hans Schikan, Chief Executive Officer, Prosensa
-
James Healy, General Partner, Sofinnova Ventures
-
Neil Warma, President & CEO, Opexa Therapeutics, Inc.
About BIO
BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO's blog chronicling "innovations transforming our world" and the BIO
Newsletter is the organization's bi-weekly email newsletter. Subscribe
to the BIO Newsletter.
Upcoming BIO Events
BIO
International Convention June 23-26, 2014 San Diego, CA (News - Alert)
BIO
Latin America Conference September 9-11, 2014 Rio de
Janeiro, Brazil
Livestock
Biotech Summit September 16-18, 2014 Sioux Falls, SD
BIO
Investor Forum October 7-8, 2014 San Francisco, CA
Pacific
Rim Summit on Industrial Biotechnology & Bioenergy December
7-9, 2014 San Diego, CA
[ Back To TMCnet.com's Homepage ]
|